Table 1.
Baseline characteristics for individuals with or without MACCEs.
| Variables | Overall (N = 7,826) |
Non-MACCE (N = 7,317) |
MACCE (N = 509) |
P-value |
|---|---|---|---|---|
| Risk groups | <0.001 | |||
| ANC-L/Non-T2D | 2,260 (28.9) | 2,139 (29.2) | 121 (23.8) | |
| ANC-H/Non-T2D | 1,940 (24.8) | 1,839 (25.1) | 101 (19.8) | |
| ANC-L/T2D | 1,642 (21.0) | 1,538 (21.0) | 104 (20.4) | |
| ANC-H/T2D | 1,984 (25.4) | 1,801 (24.6) | 183 (36.0) | |
| Baseline characteristics | ||||
| Age, years | 58.49 ± 10.15 | 58.39 ± 10.12 | 59.85 ± 10.50 | 0.002 |
| Male | 5,904 (75.4) | 5,512 (75.3) | 392 (77.0) | 0.424 |
| BMI, kg/m2 | 25.92 ± 3.20 | 25.93 ± 3.20 | 25.89 ± 3.18 | 0.819 |
| T2D | 3,626 (46.3) | 3,339 (45.6) | 287 (56.4) | <0.001 |
| Hypertension | 5,100 (65.2) | 4,750 (64.9) | 350 (68.8) | 0.087 |
| Dyslipidemia | 5,216 (66.6) | 4,858 (66.4) | 358 (70.3) | 0.076 |
| Smoking history | 4,378 (55.9) | 4,097 (56.0) | 281 (55.2) | 0.765 |
| Previous MI | 460 (5.9) | 413 (5.6) | 47 (9.2) | 0.001 |
| Previous PCI/CABG | 1,652 (21.1) | 1,527 (20.9) | 125 (24.6) | 0.055 |
| Previous stroke | 819 (10.5) | 745 (10.2) | 74 (14.5) | 0.002 |
| Previous PAD | 585 (7.5) | 548 (7.5) | 37 (7.3) | 0.924 |
| Clinical presentation | 0.759 | |||
| SAP | 2,871 (36.7) | 2,688 (36.7) | 183 (36.0) | |
| NSTE-ACS | 4,955 (63.3) | 4629 (63.3) | 326 (64.0) | |
| Laboratory tests | ||||
| Neutrophils, ∗109/L | 4.37 ± 1.76 | 4.36 ± 1.75 | 4.62 ± 1.94 | 0.001 |
| Lymphocytes, ∗109/L | 1.95 ± 0.65 | 1.95 ± 0.65 | 1.98 ± 0.67 | 0.279 |
| Platelet, ∗109/L | 174.47 ± 86.78 | 174.09 ± 86.96 | 180.02 ± 84.03 | 0.148 |
| FBG, mmol/L | 6.32 ± 2.25 | 6.30 ± 2.25 | 6.60 ± 2.21 | 0.004 |
| HbA1c, % | 6.60 ± 1.23 | 6.59 ± 1.23 | 6.79 ± 1.28 | <0.001 |
| TG, mmol/L | 1.78 ± 1.09 | 1.79 ± 1.09 | 1.76 ± 1.10 | 0.288 |
| TC, mmol/L | 4.24 ± 1.07 | 4.24 ± 1.08 | 4.22 ± 1.03 | 0.636 |
| HDL-C, mmol/L | 1.04 ± 0.28 | 1.04 ± 0.28 | 1.03 ± 0.28 | 0.424 |
| LDL-C, mmol/L | 2.53 ± 0.90 | 2.53 ± 0.91 | 2.52 ± 0.86 | 0.680 |
| hsCRP, mg/L | 3.13 ± 3.68 | 3.11 ± 3.67 | 3.47 ± 3.84 | 0.019 |
| Creatinine, μmol/L | 74.85 ± 15.32 | 74.77 ± 15.27 | 76.08 ± 15.84 | 0.061 |
| eGFR, mL/min/1.73 m2 | 103.06 ± 22.15 | 103.18 ± 22.05 | 101.39 ± 23.43 | 0.077 |
| LVEF, % | 63.75 ± 6.49 | 63.80 ± 6.46 | 63.16 ± 6.87 | 0.034 |
| Medications | ||||
| Aspirin | 7,730 (98.8) | 7,226 (98.8) | 504 (99.0) | 0.757 |
| Clopidogrel | 7,727 (98.7) | 7,224 (98.7) | 503 (98.8) | 1.000 |
| β-blocker | 7,020 (89.7) | 6,551 (89.5) | 469 (92.1) | 0.072 |
| CCB | 4,010 (51.2) | 3,742 (51.1) | 268 (52.7) | 0.539 |
| Statins | 7,505 (95.9) | 7,019 (95.9) | 486 (95.5) | 0.708 |
| Nitrate | 7,662 (97.9) | 7,165 (97.9) | 497 (97.6) | 0.790 |
| Coronary procedural data | ||||
| LM/three-vessel disease | 3,363 (43.0) | 3,095 (42.3) | 268 (52.7) | <0.001 |
| CTO lesions | 543 (6.9) | 496 (6.8) | 47 (9.2) | 0.044 |
| Bifurcation lesions | 1,566 (20.0) | 1,476 (20.2) | 90 (17.7) | 0.193 |
| Number of treated vessels | 1.41 ± 0.66 | 1.40 ± 0.66 | 1.49 ± 0.71 | 0.003 |
| Number of stents | 1.90 ± 1.04 | 1.89 ± 1.05 | 1.98 ± 1.02 | 0.017 |
| SYNTAX score | 11.78 ± 7.63 | 11.70 ± 7.59 | 12.95 ± 8.12 | 0.001 |
Values are mean ± standard deviation or n (%).
MACCE, major adverse cardiovascular and cerebrovascular events; ANC, absolute neutrophil counts; T2D, type 2 diabetes; BMI, body mass index; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; PAD, peripheral artery disease; COPD, chronic obstructive pulmonary disease; SAP, stable angina pectoris; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin A1c; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; CCB, calcium channel blocker; LM, left main; CTO, chronic total occlusion; SYNTAX, synergy between PCI with taxus and cardiac surgery.